Martine Gilard.

Martine Gilard, M.D., Ph drugstore .D.D., Bernard Iung, M.D., Patrick Donzeau-Gouge, M.D., Ph.D., Karine Chevreul, M.D., Jean Fajadet, M.D., Pascal Leprince, M.D., Alain Leguerrier, M.D., Michel Lievre, Ph.D., Alain Prat, M.D., Emmanuel Teiger, M.D., Thierry Lefevre, M.D., Dominique Himbert, M.D., Didier Tchetche, M.D.D., Bernard Albat, M.D., Alain Cribier, M.D., Gilles Rioufol, M.D., Ph.D., Arnaud Sudre, M.D., Didier Blanchard, M.D., Frederic Collet, M.D., Pierre Dos Santos, M.D., Nicolas Meneveau, M.D., Ph.D., Ashok Tirouvanziam, M.D., Christophe Caussin, M.D., Philippe Guyon, M.D., Jacques Boschat, M.D., Herve Le Breton, M.D., Frederic Collart, M.D., Remi Houel, M.D., Stephane Delpine, M.D., Geraud Souteyrand, M.D., Xavier Favereau, M.D., Patrick Ohlmann, M.D., Vincent Doisy, M.D., Gilles Grollier, M.D., Antoine Gommeaux, M.D., Jean-Philippe Claudel, M.D., Francois Bourlon, M.D., Bernard Bertrand, M.D., Eric Van Belle, M.D., Ph.D., and Marc Laskar, M.D.

The factor in the rate of the principal outcome between the hypothermia group and the control group seen at 18 to 22 months old in our previous report7 and the borderline significant difference in the rate of this outcome at 6 to 7 years of age in our current report were mainly powered by deaths, with the majority occurring within the first 18 months of life. Two various other trials10,11 show a decrease in mortality among infants 18 to 22 months old undergoing hypothermia in comparison with usual treatment. A concern with any therapy that reduces mortality among infants at risky of death and disability is the possibility of an increase in the amount of kids who survive with disabilities.